Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:11:39.394Z.
Calculation as of: 2026-10-06T14:11:39.394Z.
Quote observation: 2026-10-06T14:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f06204e81c8a2ed41a5798160e844c591f5150b644efe168084329023db9ebc4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
DiaMedica Therapeutics Inc.
Market Cap
$454.51M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$467.54M
Price/FCF Ratio
N/A
TTM Avg
826.37
3Y Avg
710.39
5Y Avg
710.39
Market Cap
$441.36M
Price/FCF Ratio
N/A
TTM Avg
3.58
3Y Avg
3.58
5Y Avg
3.58
Market Cap
$468.01M
Price/FCF Ratio
N/A
TTM Avg
26.42
3Y Avg
26.42
5Y Avg
26.42
Market Cap
$472.59M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $454.51M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $451.46M | N/A | 53.25 | 37.33 | 28.89 |
| Kamada Ltd. (KMDA)vs › | $458.09M | 17.30 | 24.31 | 87.97 | 67.12 |
| NRC Health (NRC)vs › | $462.45M | 21.37 | 27.39 | 28.55 | 30.18 |
| Cerus Corporation (CERS)vs › | $467.54M | N/A | 826.37 | 710.39 | 710.39 |
| Assembly Biosciences, Inc. (ASMB)vs › | $441.36M | N/A | 3.58 | 3.58 | 3.58 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $468.01M | N/A | 26.42 | 26.42 | 26.42 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.59M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $474.15M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $476.17M | N/A | 5.51 | 5.54 | 11.44 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
